key: cord-0900122-63oerjse
authors: Husain, S. Ali; Tsapepas, Demetra; Paget, Kathryn F.; Chang, Jae-Hyung; Crew, R. John; Dube, Geoffrey K.; Fernandez, Hilda E.; Morris, Heather K.; Mohan, Sumit; Cohen, David J.
title: Post-vaccine anti-SARS-CoV-2 spike protein antibody development in kidney transplants recipients
date: 2021-04-23
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2021.04.017
sha: 5c450933bfb8b11b7b788cb860c686e43168dc58
doc_id: 900122
cord_uid: 63oerjse

nan

Solid organ transplant recipients are at an elevated risk of severe COVID-19, and early reports also suggest impaired response after the first dose of a SARS-CoV-2 mRNA vaccine series. [1] [2] [3] Due to concerns about vaccine immunogenicity, all kidney transplant recipients at our center are recommended to undergo anti-SARS-CoV-2 spike protein IgG ("anti-spike antibody") testing 2-6 weeks after completing their vaccination series in full.

As of 3/29/2021, 28 recipients at our center have undergone such testing, with median age 66 years and median time since transplant 8.7 years (range 1.0-15.8) ( Table 1 ). Only 3 patients had a history of PCRpositive SARS-CoV2 infection. Antibody testing was performed using anti-spike IgG immunoassay (DiaSorin Liaison® assay via LabCorp®, n=5, or Roche® Elecsys®, n=23). Each of these clinical assays initially was designed to identify the presence of an adaptive immune response to SARS-CoV-2 infection.

The Roche assay has a reported sensitivity of 96.6% (95% CI 93.4 -98.3%) and specificity of 100% (95% CI: 99.7 -100%). 4 The DiaSorin Liaison assay has a reported sensitivity of 97.6% (95% CI 87.4% -99.6%) and specificity of 99.3% (95% CI 98.6-99.6%). 4 Among included patients, only 7 (25%) had detectable anti-spike IgG ("antibody-positive"), whereas 21 (75%) did not have detectable antibodies ("antibody-negative"). Demographics and clinical characteristics, including kidney function, of antibody-positive and antibody-negative patients were similar, although the small sample size precluded formal comparisons (Table 1) 

COVID-19 in solid organ transplant: A multi-center cohort study

Immunogenicity of a Single Dose of SARS-CoV-2

Messenger RNA Vaccine in Solid Organ Transplant Recipients

COVID-19 in solid organ transplant recipients: Initial report from the US epicenter

Food and Drug Administration

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Kinetics of antibody response to influenza vaccination in renal transplant recipients

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

SAH is supported by the National Center for Advancing Translational Sciences (KL2 TR001874). SM is supported by the National Science Foundation (NSF Grant 2032726).

The authors declare that they have no financial conflicts of interest to disclose.J o u r n a l P r e -p r o o f

J o u r n a l P r e -p r o o f